Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Hold” by Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average rating of “Hold” from the five research firms that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $40.75.

A number of equities analysts have weighed in on the stock. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Piper Sandler cut shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research report on Friday, May 10th. Finally, Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price objective for the company from $41.00 to $44.00 in a research report on Friday, June 7th.

Insider Transactions at Collegium Pharmaceutical

In other news, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the transaction, the director now owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the transaction, the director now owns 44,775 shares of the company’s stock, valued at $1,446,232.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the transaction, the executive vice president now directly owns 105,902 shares in the company, valued at approximately $3,598,549.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,502 shares of company stock valued at $3,540,796. Insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the business. Principal Securities Inc. bought a new position in Collegium Pharmaceutical in the fourth quarter worth about $40,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Collegium Pharmaceutical by 320.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after purchasing an additional 2,877 shares during the period. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $204,000. Assetmark Inc. increased its stake in shares of Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after purchasing an additional 1,108 shares during the period. Finally, Gallacher Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $223,000.

Collegium Pharmaceutical Stock Up 1.0 %

Shares of NASDAQ COLL opened at $32.36 on Thursday. Collegium Pharmaceutical has a 12-month low of $20.83 and a 12-month high of $40.95. The company has a market cap of $1.06 billion, a P/E ratio of 13.48 and a beta of 0.93. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The stock has a fifty day moving average price of $33.64 and a 200 day moving average price of $34.40.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.04). Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The company had revenue of $144.92 million during the quarter, compared to analyst estimates of $147.04 million. Research analysts anticipate that Collegium Pharmaceutical will post 5.57 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.